Related references
Note: Only part of the references are listed.Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Laura M. Spring et al.
CLINICAL CANCER RESEARCH (2020)
Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy
Susie Sun et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints
Gaiane M. Rauch et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment)
M. E. M. van der Noordaa et al.
BREAST (2018)
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer
R. F. D. van la Parra et al.
BRITISH JOURNAL OF SURGERY (2018)
Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour
Soo-Yeon Kim et al.
EUROPEAN RADIOLOGY (2018)
RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial
Joerg Heil et al.
BMC CANCER (2018)
NRG Oncology BR005: Phase II trial assessing accuracy of tumor bed biopsies (Bx) in predicting pathologic response in patients (Pts) with clinical/radiological complete response (CR) after neoadjuvant chemotherapy (NCT) in order to explore the feasibility of breast-conserving treatment (BCT) without surgery.
Mark Basik et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Dynamic Contrast-enhanced Breast MRI for Evaluating Residual Tumor Size after Neoadjuvant Chemotherapy
Soo-Yeon Kim et al.
RADIOLOGY (2018)
Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy
Alison U. Barron et al.
JAMA SURGERY (2018)
Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy
Henry M. Kuerer et al.
ANNALS OF SURGERY (2018)
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy
Henry M. Kuerer et al.
ANNALS OF SURGERY (2018)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery
Audree B. Tadros et al.
JAMA SURGERY (2017)
Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials
Henry M. Kuerer et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?
Yara Feliciano et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?
Joerg Heil et al.
EUROPEAN JOURNAL OF CANCER (2016)
Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials
Raquel F. D. van la Parra et al.
BREAST CANCER RESEARCH (2016)
Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques
Joerg Heil et al.
BRITISH JOURNAL OF CANCER (2015)
Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy
Tari A. King et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Meta-Analysis of Magnetic Resonance Imaging in Detecting Residual Breast Cancer After Neoadjuvant Therapy
Michael L. Marinovich et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review
M. B. I. Lobbes et al.
INSIGHTS INTO IMAGING (2013)
Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy
Nehmat Houssami et al.
EUROPEAN JOURNAL OF CANCER (2012)
Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype
Claudette E. Loo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET (2010)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
AU Buzdar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
